Business Wire

Bona Germany Welcomes Emission-Free, Scania Electric Truck to Facility in Limburg

1.12.2021 10:30:00 EET | Business Wire | Press release

Share

Bona®, a global, sustainably-driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, and Scania, one of the world's leading providers of transport solutions, hosted an event yesterday to welcome Bona’s first electric truck to its facility in Limburg, Germany. The Scania innovated truck is from the Scania P series and will offer an emission-free transport system for Bona’s operations in Limburg and the surrounding area. It is the first of its kind to be operated in Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005952/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bona and Scania hosted an event on November 30 to welcome Bona’s first electric truck to its facility in Limburg, Germany. Pictured from left to right: Christian Löher, Managing Director Bona Vertriebsgesellschaft mbH Deutschland / Regional Sales Manager Region Central; Dr. Thomas Brokamp, Managing Director, Bona GmbH Deutschland; Monika Sommer, Hauptgeschäftsführerin IHK Limburg / CEO of the Chamber of Commerce and Industry, Region Limburg / Weilburg; Jörg Sauer, Kreisbeigeordneter Landkreis Limburg Weilburg / District Councilor; Dr. Marius Hahn, Bürgermeister Limburg an der Lahn / Mayor; Christian Hottgenroth, Direktor Verkauf Lkw Scania Deutschland Österreich / Director of Sales Germany / Austria; Thorsten Kusch, Supply Chain Director for EMEA / APAC at DC 1, Bona (Photo: Business Wire)

"Bona is committed to incorporating and pursuing sustainable products, systems, and practices throughout the company and the new Scania electric truck is an important milestone in our journey to a greener future,” said Dr. Thomas Brokamp, Managing Director, Bona Germany. “Scania advised us well on the choice of our electric vehicle and gave us a good introduction to this new technology. The Scania electric truck is perfectly tailored to our needs and areas of operation.” The battery-electric truck will act as a city shuttle, making multiple trips a day to transport finished products from the production plant in the south of the city to the distribution center in the north, just under six kilometers away. Approximately 21 euro pallets can be accommodated in the loading area on each tour.

A POWERFUL DRIVE SYSTEM AND COMFORTABLE RIDE

The new model in the Scania P series, called the Scania 25 P, was specially designed for inner-city use and is characterized by comfortable access to the cab and excellent traffic visibility. The number in the model designation indicates the power that the truck travels, up to 230 kW (312 hp) rated engine power, which is enough power to move the three-axle truck's permissible weight of 26 tons with ease.

"The electric powertrain shines, especially at low engine speeds and in starting situations, with significantly better acceleration and more tractive power compared to a diesel truck," said Christian Hottgenroth, Director of Truck Sales, Scania Germany Austria. “In practice, drivers can therefore look forward to rapid acceleration and short response times from the drive.”

The Scania 25 P stores the energy for propulsion in five lithium-ion batteries, each with a capacity of 33 kW/h. "The electric range depends primarily on the factors of driving style, load, as well as topography," Hottgenroth explained further. Under optimal conditions, the drive batteries with the total capacity of 165 kW/h are designed for a range of up to 110 kilometers, while 70 to 90 kilometers can be expected in real driving conditions. For Bona’s use in the city of Limburg, which will average approximately 50 kilometers per day, the power is completely sufficient for the planned operating profile.

POWERED WITH SUSTAINABLE ENERGY

Because Bona’s Limburg facility is equipped with solar panels, the new Scania truck will be fueled by green electricity generated by a powerful photovoltaic system on the roof of the large hall. The fully electric truck is charged with direct current and is equipped with a charging capacity of 130 kW, which allows the batteries to be fully charged in about an hour at 20 percent capacity. If more range is required, a stop of half an hour at the charging station is enough to charge energy for another 50 or 60 kilometers.

“Moving to an emission-free vehicle is an important part of our broader sustainability journey and part of our commitment to be a good citizen. Due to high traffic the city of Limburg has a problem with excessively high nitrogen dioxide levels. The main source are diesel vehicles, and it is now extremely likely a ban for these vehicles is coming 1st of April 2022 for Limburg. With our emission-free truck we can make a valuable contribution in Limburg to lower nitrogen dioxide levels and to global decarbonization," said Dr. Brokamp. The fact that the electric truck from Scania also runs locally with zero emissions and is virtually noise-free due to its low-noise drive are also benefits of the all-electric truck.

Bona is in the process of finalizing the electric charging station, which is slated for completion by early 2022.

ABOUT BONA

Bona is a family-owned, sustainably-driven company that supplies products for installing, renovating, maintaining, and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber, and laminate. Bona’s turnover is 3.1bn SEK (EUR 307 million) 2020. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 600 employees, and 5 factories. For more, visit www.bona.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heather Lindemann | Bona
+1 (800) 872-5515
heather.lindemann@bona.com

Rüdiger Weil | Bona Germany
+49 6431 4008-134
Ruediger.Weil@bona.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye